Clinical Trial: Allo HSCT for High Risk Hemoglobinopathies

U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06872333) titled 'Allo HSCT for High Risk Hemoglobinopathies' on March 05.

Brief Summary: A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

Study Start Date: Nov. 19, 2024

Study Type: INTERVENTIONAL

Condition: Graft Failure Sickle Cell Disease Hemoglobinopathies

Intervention: DRUG: Alemtuzumab

Alemtuzumab (Campath) will be administered IV over 2 hours on day -8 to day -4.

RADIATION: Total Body Irradiation

400 cGy in 2 split fractions will be administe...